07.10.2015 • News

Covestro Share Launch Successful

German engineering plastics producer Covestro and its parent company Bayer successfully placed 62.5 million shares of the former Bayer MaterialScience in the Prime Standard of the Frankfurt Stock Exchange on Oct. 6.

The issue was three times oversubscribed, and stock market watchers said the paper was picked up by investors based in Germany and in English-speaking countries, including the US.

After starting the first day of trading at an issue price of €24, the listing price quickly rose to finally settle above €26 – a gain of more than 12%. Toward the end of the book-building process, the proposed range had been taken back from €26.50-35.50 per share to €21.50-34.50, which analysts said boosted its prospects.

Although originally planning the launch proceeds at €2.5 billion, the Leverkusen giant, which is repositioning itself as a pure life science player, dropped its target by €1 billion to keep the new standalone company’s net indebtedness at €4 billion.

The Covestro shares are also being offered to investors in Luxembourg in addition to Frankfurt. Following the successful placement, Bayer’s stake in its former sub-group has sunk to 69%, and the German group is aiming for future gradual reductions.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read